Co-Diagnostics, Inc. (CODX)
Oxford Ledge is still expanding full research coverage of CODX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Co-Diagnostics develops and sells molecular diagnostic tests using proprietary PCR technology to detect infectious diseases and genetic traits.
SEC filings
- 8-K Entry into material agreement; 3.02; Other material event; Financial statements and exhibits 2026-05-21
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-05-14
- 10-K Annual financial report with audited statements 2026-03-31
- 8-K Results of operations / financial condition; Regulation FD disclosure; Financial statements and exhibits 2026-03-31
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CODX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CODX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.